Vanna Chiarion‐Sileni
0000-0001-9191-9124
Publication & Citation Trends
Publications
0 total
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study.
Cited by 6
Semantic Scholar
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial
Cited by 3
Semantic Scholar
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study.
Cited by 2
Semantic Scholar
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
Cited by 9
Semantic Scholar
A model workflow for microfluidic enrichment and genetic analysis of circulating melanoma cells
Cited by 0
Semantic Scholar
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020 OA
Cited by 3
Semantic Scholar
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.
Cited by 3
Semantic Scholar
Research Topics
Melanoma and MAPK Pathways
(195)
CAR-T cell therapy research
(156)
Cancer Immunotherapy and Biomarkers
(146)
Cutaneous Melanoma Detection and Management
(140)
Immunotherapy and Immune Responses
(75)
Affiliations
Université Claude Bernard Lyon 1
University of Siena
Memorial Sloan Kettering Cancer Center
Humanitas University
University of Padua